

**ETHNIC DIFFERENCES IN ASSOCIATIONS BETWEEN BLOOD PRESSURE AND STROKE IN SOUTH ASIAN AND EUROPEAN MEN**

**Running title:** BP and stroke in South Asians and Europeans

**Authors:** Sophie V Eastwood MSc<sup>1</sup>, Therese Tillin MSc<sup>1</sup>, Nish Chaturvedi MD<sup>1</sup>, Alun D Hughes PhD<sup>1</sup>

**Affiliations:** <sup>1</sup>UCL Institute of Cardiovascular Science, University College London, Gower Street, London, United Kingdom, WC1E 6BT.

**Word count:** 5999

**Number of figures:** 2

**Corresponding author:** Dr Sophie V Eastwood, UCL Institute of Cardiovascular Science, UCL, Gower Street, London, United Kingdom, WC1E 6BT. Email:

[sophie.eastwood@ucl.ac.uk](mailto:sophie.eastwood@ucl.ac.uk), Tel: +44 (0)207 679 9434, Fax: +44 (0)20 7679 3001.

**Abstract**

It is unknown whether associations between blood pressure and stroke vary between Europeans and South Asians, despite higher stroke rates in the latter. We report findings from a UK cohort study of 1375 European and 1074 South Asian men, not receiving anti-hypertensive medication, aged 40-69 years at baseline (1988-91). Assessment included blood pressure, blood tests, anthropometry, and questionnaires. Incident stroke was established at 20 years from death certification, hospital and primary care records, and participant report. South Asians had higher systolic (SBP), diastolic (DBP) and mean arterial (MAP) blood pressure than Europeans, and similar pulse pressure (PP). Associations between SBP or DBP and stroke were stronger in South Asians than Europeans, after adjustment for age, smoking status, waist/hip ratio, total/HDL-cholesterol ratio, diabetes, fasting glucose, physical activity, and heart rate (SBP: Europeans;(OR(95% CI) 1.22(0.98,1.51), South Asians;1.56(1.24,1.95), ethnic difference  $p=0.04$ , DBP: Europeans;0.90(0.71,1.13), South Asians;1.68(1.32,2.15),  $p<0.001$ ). Haemodynamic correlates of stroke risk differed by ethnicity: in combined models, MAP but not PP was detrimentally associated with stroke in South Asians, whilst the converse was true for Europeans. The combination of hyperglycaemia and hypertension appeared particularly detrimental for South Asians. There are marked ethnic differences in associations between BP parameters and stroke. Undue focus on SBP for risk prediction, and current age and treatment thresholds may be inappropriate for individuals of South Asian ancestry.

**Keywords:** blood pressure, stroke, ethnic differences, South Asians

## **Introduction**

Stroke is the second leading cause of death globally, with high blood pressure (BP) the strongest risk factor.<sup>1-3</sup> South Asians experience a 1.5-2 fold higher stroke risk than Europeans.<sup>4</sup> Differences in hypertension prevalence between South Asians and Europeans do not explain the greater stroke risk in South Asian groups,<sup>5, 6</sup> however associations between BP and its constituents (i.e. systolic BP (SBP), diastolic BP (DBP), or, from a haemodynamic perspective, mean arterial pressure (MAP) and pulse pressure (PP)) and stroke risk have not been compared directly in South Asians and Europeans. This is important as studies in European-origin populations indicate that SBP or PP are the major drivers of risk;<sup>7</sup> consequently it has been proposed that SBP should be the sole target for intervention,<sup>8</sup> and many risk estimators only include SBP in their calculations.<sup>9, 10</sup> Such assumptions need to be tested in non-European populations. Furthermore, diabetes is much more prevalent in South Asian than European populations,<sup>5</sup> and increases stroke risk independent of other cardiovascular risk factors,<sup>11</sup> but the influence of hyperglycaemia on associations between BP and stroke risk in the former group is unexplored.

Using data from a community-based follow-up study, we compared associations between BP constituents and stroke in South Asian and European men, and secondly explored reasons for differences, e.g. inter-ethnic variation in glycaemia.

## **Methods**

### *Study participants and design*

The SABRE study is a multi-ethnic cohort study; details are published elsewhere.<sup>12</sup>

Participants aged 40-69 years at baseline (1988-1991, n=4857) were randomly selected from primary care physician lists and workplaces in north-west London. South Asian participants

were first-generation migrants originating from the Indian subcontinent. All participants were followed for death, hospitalisation, and primary care consultations from baseline to 2011 (outcome data were available for 4196). We report findings from a subset of 1375 European and 1074 South Asian men without stroke at baseline, who were not in receipt of baseline anti-hypertensive medication (figure 1).

All participants gave written informed consent. Approval for the baseline study was obtained from Ealing, Hounslow and Spelthorne, Parkside and University College London research ethics committees, and at follow-up from St. Mary's Hospital Local Research Ethics Committee (reference: 07/HO712/109).

#### *Baseline and follow-up measurements*

Participants underwent anthropometric measurement, and completed a health, lifestyle and occupation questionnaire. Physical activity comprised the total weekly energy expended (MJ) on sports, walking, cycling and daily activities. Circulating lipids, fasting and post-load glucose, and insulin and HbA<sub>1c</sub> were measured, as described.<sup>12</sup> Physician diagnosis or World Health Organization 1999 criteria for fasting and oral glucose tolerance test blood glucose measurements<sup>13</sup> defined diabetes. HOMA2-IR was used to quantify insulin resistance.<sup>14</sup> Renal function was quantified by estimated glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) validated equations.<sup>15</sup> Between 2008 and 2011, survivors were invited for examination at St. Mary's hospital, London. New cases of diabetes since baseline were identified from record review, questionnaire, clinic blood results, or death certificate data (ICD-9: 2500-2509, ICD-10: E100-E149). Atrial fibrillation or flutter (AF) at follow-up was established from record review, questionnaire, and hospital episode statistics (HES) (ICD-9: 4273, ICD-10: I48).

Incident stroke was defined as the first post-baseline event from the following sources: death certification data (ICD-9: 430-439, ICD-10: I600-I698), HES (ICD codes as above), primary care record review adjudicated by two clinicians, as per Anglo-Scandinavian Cardiac Outcomes Trial criteria<sup>16</sup> and participant report of physician-diagnosed stroke with duration of symptoms  $\geq 24$  h.

Seated resting brachial blood pressure and heart rate were measured at baseline after a 15 minute rest using a random zero sphygmomanometer (Hawksley, London, United Kingdom) and at follow-up using an Omron 705IT; the mean of two measurements from each time point was used in analyses. A correction was applied to follow-up BP measurements (SBP: minus 1.35 mmHg, DBP: minus 1.97 mmHg) to ensure comparability with those at baseline, since the Hawksley random zero sphygmomanometer may under-estimate BP when compared with a standard mercury sphygmomanometer<sup>17</sup>. Concordance correlation coefficients<sup>18</sup> for 30 inter-observer repeated measurements of follow-up SBP and DBP were 0.78 and 0.89 respectively. Mean arterial pressure (MAP) was calculated as  $DBP + ((1/3) \times (SBP - DBP))$ .

### *Statistical analysis*

Baseline characteristics were compared by follow-up status, incident stroke and ethnicity. Logistic and linear regression methods determined age-adjusted differences.

Associations between a 1 standard deviation (SD) increase in SBP, DBP, MAP, and PP and incident stroke were studied using age-adjusted logistic regression models. We then additionally adjusted these models for potential confounders (smoking, waist/hip ratio (WHR), total/ HDL-cholesterol (TC/HDL) ratio, diabetes, fasting glucose, physical activity, and heart rate). Smoking status and TC/HDL ratio were deemed potential confounders a

priori,<sup>19</sup> whilst the remainder were selected on the basis of associations ( $p < 0.10$ ) with stroke in either ethnic group (table 1). Interactions between BP measures and ethnicity were sought in all models. Additionally, we inspected models with BP measures in combination (SBP + DBP, or MAP + PP) by ethnicity. We elected to use logistic regression as the proportional hazards assumption was violated for several models when using Cox regression techniques. We further explored ethnic differences in associations between BP and stroke by inspecting interaction terms between BP measures and baseline diabetes, fasting glucose, HbA<sub>1c</sub>, or HOMA2-IR in models of stroke for each ethnic group. This analysis was extended by graphically displaying stroke incidence by dichotomised SBP or DBP plotted against dichotomised HbA<sub>1c</sub> or fasting glucose for each ethnic group. Next, we compared associations between age and SBP or DBP in each ethnic group, to establish whether age-related trends in BP differed by ethnicity. Subsequently, for participants with BP data at follow-up, we subtracted follow-up BP (with correction applied, see earlier) from baseline BP to elucidate ethnic differences in BP change over time, whether associations between BP change and stroke risk varied by ethnicity, and if this effect was modified by diabetes. Following this, for individuals in receipt of anti-hypertensive medication, we examined ethnic differences in SBP, DBP and BP control (defined as  $BP \leq 140/90$  mmHg) by diabetes status at follow-up. Finally, we contrasted rates of anti-hypertensive use by ethnicity for people with  $BP > 140/90$  mmHg at baseline and follow-up, to establish ethnic differences in hypertension management.

Sensitivity analyses were conducted by: a) including individuals in receipt of baseline anti-hypertensive medication, adding 10/5 mmHg to BPs of those receiving treatment,<sup>20</sup> b) excluding people with baseline diabetes, c) adjusting for diabetes as a time-varying covariate, d) adjusting for HbA<sub>1c</sub> or HOMA2-IR instead of fasting glucose, e) using the alternative

formula for MAP ( $\text{MAP} = \text{DBP} + 0.4 \times \text{PP}$ ) proposed by Bos,<sup>21</sup> f) adjusting for follow-up use of anti-thrombotic medication (anti-platelets or anti-coagulant agents), g) adjusting for presence of atrial fibrillation/ flutter at follow-up (the latter two variables were not available at baseline), h) adjusting for body mass index instead of waist/ hip ratio and i) additionally adjusting for eGFR in CVD risk factor-adjusted models (as a sensitivity analysis due to lower data availability). We repeated analyses by age sub-group (<55 years and  $\geq 55$  years).

## Results

A total of 1375 (87%) European and 1074 (88%) South Asian men had complete data for baseline BP measures and stroke follow-up (figure 1). There were no consistent differences in baseline characteristics by follow-up status. Over a median of 20 years follow-up, incident stroke was higher in South Asians (n=102, 10%,  $p=0.02$ ) than Europeans (n=104, 8%). South Asian men were more centrally obese, with more adverse lipid and glycaemic profiles and blood pressure measures than European men (table 1). The exception to this was PP, which was similar by ethnicity.

All measures of BP (SBP, DBP, MAP and PP) were strongly positively associated with incident stroke in South Asians, even on multivariable adjustment (table 2). In contrast, with the exception of PP, associations were either weaker (SBP) or absent for Europeans. These ethnic differences in associations between BP and stroke risk were significant as interactions. When both SBP and DBP were included in models, SBP was positively, and DBP negatively related to stroke risk in Europeans, whereas in South Asians, DBP remained positively associated with stroke risk (ethnicity interaction  $p < 0.001$ ), in addition to SBP. In the MAP + PP models, PP but not MAP was associated with stroke in Europeans, whereas the opposite was true for South Asians; ethnicity interactions were present for both parameters.

There were no significant interactions for associations between each BP measure and diabetes, fasting glucose, HbA<sub>1c</sub> or HOMA2-IR (the latter three exposures as continuous variables) and stroke in age-adjusted models. However, inspection of graphical plots of incident stroke by dichotomised SBP or DBP plotted against dichotomised HbA<sub>1c</sub> indicated that participants in both the highest category for blood pressure measure and HbA<sub>1c</sub> appeared to have greater risk, compared with those in the lowest categories for each parameter, in South Asians but not Europeans (SBP: Europeans; (age-adjusted OR (95% CI) 0.80 (0.41, 1.54), South Asians; 5.11(2.28,11.47), ethnic difference  $p=0.001$ , DBP: Europeans; 0.77(0.39,1.54), South Asians; 5.96(2.25,15.77), ethnic difference  $p=0.001$ ) (figure 2). Results were similar for fasting glucose. Relationships between SBP or DBP and age did not vary with ethnicity, nor were consistent ethnic differences observed for BP change between baseline and follow-up. Equally, there were no ethnic differences in associations between BP change measures and stroke. Of the original participants, 534 Europeans and 444 South Asians additionally attended the follow-up clinic in 2008-11. There were no ethnic differences in BP control in these individuals (supplementary table S1) or in the proportions of people with BP>140/90 mmHg taking anti-hypertensive medication at baseline or follow-up (baseline: 19% Europeans vs. 23% South Asians,  $p=0.39$ , follow-up: 66% vs. 86%,  $p=0.25$ ). Sensitivity analyses showed that inclusion of participants on baseline anti-hypertensive medication (Europeans: 155/1530 (10%) and South Asians: 154/1228 (13%),  $p=0.04$ , table 3), exclusion of participants with baseline diabetes (supplementary table S2), adjustment for diabetes development as a time-varying covariate (supplementary table S3) adjustment for HbA<sub>1c</sub> or HOMA2-IR instead of fasting glucose, use of an alternative formula for MAP,<sup>21</sup> adjustment for anti-thrombotic medication use at follow-up (Europeans: 395/712 (55%), South Asians: 401/584 (69%),  $p<0.001$ ) or AF at follow-up (Europeans: 96/712 (13%) and



South Asians 43/584 (7%),  $p < 0.001$ ) (table 4), substitution of BMI for WHR and additional adjustment for eGFR gave similar results to the main analyses. A sub-group analysis contrasting associations by younger vs. older age group (<55 years vs.  $\geq 55$  years) demonstrated little evidence for associations between BP measures and stroke risk in younger Europeans, whereas SBP and PP had strong positive associations with stroke in the older group. In contrast, for South Asians, associations between BP measures and stroke did not differ greatly by age group and were similar to those reported in the main analyses (supplementary table S4).

## Discussion

South Asians had modestly higher SBP, DBP, and MAP than Europeans, though PP was similar. We report the following novel findings: 1) SBP, DBP, and MAP were more adversely associated with stroke in South Asians than Europeans, 2) when MAP + PP were considered together, PP but not MAP was detrimentally associated with stroke in Europeans, whilst the converse was true for South Asians, these findings persisted on adjustment for other cardiovascular risk factors, 3) associations between BP and stroke risk were greater in older ( $\geq 55$  years) than younger Europeans, but similar by age group in South Asians, 4) the combined effects of high BP and high glycaemia appeared to be more deleterious in South Asians than Europeans.

Our findings of higher blood pressure in South Asians than Europeans accord with most<sup>5, 6</sup> but not all<sup>22</sup> previous studies. Also consistent with earlier work<sup>5, 6</sup> we showed only marginally elevated SBP and DBP (mean difference +2mmHg and +3mmHg respectively) in South Asians when compared with Europeans; disparities that do not adequately explain the 1.5-fold higher stroke incidence in the former group<sup>2, 4</sup>.

A novel finding was that SBP, DBP and MAP were more strongly associated with stroke in South Asians than Europeans. South Asians had more adverse glycaemic profiles than Europeans, thus we investigated whether the excess risk of stroke from high BP in South Asians was linked to greater hyperglycaemia. Neither excluding people with diabetes at baseline, nor adjusting for diabetes, hyperglycaemia, or insulin resistance in the main models altered the observed ethnic difference in the impact of BP measures on stroke. Nevertheless, the combination of high BP and glycaemia as dichotomized variables appeared more deleterious for South Asians than Europeans. We have previously shown that South Asians have poorer cerebral autoregulation than Europeans, in part due to greater levels of hyperglycaemia.<sup>23</sup> This may enhance the South Asian vulnerability to stroke.

Since DBP tends to plateau or fall in Europeans after approximately 55 years of age,<sup>24</sup> we postulated that the greater effects of DBP on stroke risk in South Asians were due to differences in this age-related DBP decline; this was not the case, nor were there ethnic differences in the impact of BP change over 20 year follow-up on stroke risk. Additionally we explored the influence of medication use over follow-up. Our main analyses excluded people in receipt of anti-hypertensive medication at baseline, but we also showed no ethnic differences in either BP control ( $BP \leq 140/90$  mmHg) for participants receiving anti-hypertensive medication at follow-up, or anti-hypertensive receipt for those with  $BP > 140/90$  mmHg at baseline or follow-up. This suggests ethnic differences in BP management and control in those with hypertension are unlikely to contribute to the excess risk of stroke in South Asians with higher BP, commensurate with findings from UK primary care data.<sup>25</sup> In addition, adjustment for anti-thrombotic use at follow-up, which was greater in South Asians than Europeans, did not alter the ethnic differential in associations between SBP, DBP, or MAP and stroke. Though we did not have data on use of anti-thrombotic medication at

baseline, use of these drugs in primary prevention was not widespread until the late 1990's, hence any confounding effects are likely to be less than for contemporary cohorts. Our follow-up data indicated a greater prevalence of atrial fibrillation/ flutter (AF) in Europeans than South Asians (baseline data were unavailable), in keeping with previous findings,<sup>26</sup> however, a sensitivity analysis restricted to follow-up data indicated that AF did not have an important impact on associations between BP and stroke in either ethnic group. Other possible explanations for the ethnic differences in these associations include inter-ethnic variation in diurnal BP. However a previous study reported no ethnic differences in 24 hour BP, including nocturnal dipping,<sup>27</sup> and unpublished data from the SABRE cohort is consistent with this. Alternatively, genetic or epigenetic factors may contribute; we were unable to explore these further.

We contrasted the relative contribution of the hemodynamic components of BP: PP and MAP, to stroke risk by examining models featuring these measures in combination. These indicated that PP was more adversely related to stroke than MAP in Europeans, consistent with the postulated role of arterial stiffness in cardiovascular risk for this ethnic group, demonstrated in the Framingham Heart Study.<sup>7</sup> Conversely, MAP was much more adversely related to stroke risk than PP in South Asians. This may imply that increased peripheral resistance might be relatively more important to stroke risk in this group.<sup>28</sup> Reasons for these ethnic differences are unknown, but they are consistent with evidence indicating a comparatively greater prevalence of intracranial and small vessel disease in South Asian people with stroke<sup>5, 26</sup> and increased microvascular disease in South Asian individuals.<sup>29</sup> These mechanisms could be further studied by observing ethnic differences in microvascular responses to PP and MAP, e.g. using near infra-red spectroscopy (NIRS).<sup>30</sup> If stroke

pathogenesis differs by ethnicity, this has important implications for risk management strategies, particularly for measures of BP.

This longitudinal study is unique in comparing associations between BP and stroke in Europeans and South Asians, with adequate power to show ethnic differences and excellent follow-up rates. A single BP measurement may not adequately represent lifetime exposure, however we found no evidence of marked differences in age-related changes in BP by ethnicity and imprecision in measurement of exposures is more likely to obscure differences. Since the main analyses did not involve comparison of baseline and follow-up BPs, baseline/follow-up differences in BP ascertainment method are unlikely to have affected results. Potential confounders may have varied over time, especially use of anti-hypertensive, lipid-lowering and anti-thrombotic medication. We did not have sufficient power to compare stroke sub-types or fatal and non-fatal events, though the majority of strokes in both ethnic groups are ischaemic in nature<sup>31</sup> and data from the Prospective Studies Collaboration suggests the BP-associated risks for ischaemic and haemorrhagic strokes are similar.<sup>2</sup> Our study was limited to men and the South Asian population was of Indian origin, mostly Punjabi Sikhs, resident in the UK, thus caution should be exercised in applying these findings to women and other South Asian sub-groups.

### **Perspectives**

To summarise, in this longitudinal comparison of UK ethnic groups, we have shown that SBP, and particularly DBP and MAP, were more strongly associated with stroke risk in South Asians than Europeans, independent of other cardiovascular risk factors. Associations remained strong across the age spectrum in South Asians, unlike Europeans where associations were apparent only in those aged  $\geq 55$  years. If substantiated, our findings support the need for trials of BP reduction beyond current thresholds, and in younger individuals, to

address the greater stroke risk in South Asian groups. The majority of cardiovascular risk scores guiding primary prevention utilise SBP alone,<sup>9, 10</sup> and it has been proposed that DBP may be largely immaterial to CVD risk and does not warrant measurement in clinical practice.<sup>8</sup> Our findings suggest that DBP is an important therapeutic target for stroke prevention in South Asian men.

### **Acknowledgements**

All authors contributed to study design and interpretation, and approved the final manuscript. SVE had full access to all the data in the study, performed the statistical analyses, wrote the first draft of the manuscript and has primary responsibility for the final content and decision to submit for publication. The authors thank all members of the SABRE group for their contributions to study design, management, data collection and analyses, especially Drs. Ajay Gupta and Neil Chapman for their assistance in identifying stroke events.

### **Sources of funding**

The study was funded at baseline by the UK Medical Research Council, Diabetes UK, and the British Heart Foundation, and at follow-up by the Wellcome Trust and British Heart Foundation. Funders played no role in the study design, conduct or analysis, or the decision to submit the manuscript for publication. The SABRE study group is entirely independent from the funding bodies.

### **Conflicts of interest**

None.

## References

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global and regional burden of stroke during 1990-2010: Findings from the global burden of disease study 2010. *Lancet*. 2014;383:245-254.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903-1913.
3. Lawes CM, Bennett DA, Parag V, Woodward M, Whitlock G, Lam TH, Suh I, Rodgers A. Blood pressure indices and cardiovascular disease in the asia pacific region: A pooled analysis. *Hypertension*. 2003;42:69-75.
4. Tillin T, Hughes AD, Mayet J, Whincup P, Sattar N, Forouhi NG, McKeigue PM, Chaturvedi N. The relationship between metabolic risk factors and incident cardiovascular disease in europeans, south asians, and african caribbeans: Sabre (southall and brent revisited) -- a prospective population-based study. *Journal of the American College of Cardiology*. 2013;61:1777-1786.
5. Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, Kelemen L, Yi C, Lonn E, Gerstein H, Hegele RA, McQueen M. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in canada: The study of health assessment and risk in ethnic groups (share). *Lancet*. 2000;356:279-284.

6. Chowdhury TA, Lasker SS, Mahfuz R. Ethnic differences in control of cardiovascular risk factors in patients with type 2 diabetes attending an inner london diabetes clinic. *Postgraduate medical journal*. 2006;82:211-215.
7. Franklin SS, Gustin Wt, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The framingham heart study. *Circulation*. 1997;96:308-315.
8. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. *Lancet*. 2008;371:2219-2221.
9. Qrisk2-2014 risk calculator.2015.
10. Framingham heart study cardiovascular disease (10 year risk).2015.
11. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375:2215-2222.
12. Tillin T, Forouhi NG, McKeigue PM, Chaturvedi N. Southall and Brent revisited: Cohort profile of sabre, a uk population-based comparison of cardiovascular disease and diabetes in people of european, indian asian and african caribbean origins. *International journal of epidemiology*. 2012;41:33-42.
13. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. 1999.
14. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (homa) evaluation uses the computer program. *Diabetes care*. 1998;21:2191-2192.

15. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. Estimating glomerular filtration rate from serum creatinine and cystatin c. *The New England journal of medicine*. 2012;367:20-29.
16. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Rationale, design, methods and baseline demography of participants of the anglo-scandinavian cardiac outcomes trial. Ascot investigators. *Journal of hypertension*. 2001;19:1139-1147.
17. Mackie A, Whincup P, McKinnon M. Does the Hawksley random zero sphygmomanometer underestimate blood pressure, and by how much? *Journal of human hypertension*. 1995;9:337-343.
18. Lin LI. A concordance correlation coefficient to evaluate reproducibility. *Biometrics*. 1989;45:255-268.
19. Kinlay S. Changes in stroke epidemiology, prevention, and treatment. *Circulation*. 2011;124:e494-496.
20. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. *Hypertension*. 2003;41:207-210
21. Bos WJ, Verrij E, Vincent HH, Westerhof BE, Parati G, van Montfrans GA. How to assess mean blood pressure properly at the brachial artery level. *Journal of hypertension*. 2007;25:751-755.
22. Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG, Harland J, Patel S, Ahmad N, Turner C, Watson B, Kaur D, Kulkarni A, Laker M, Tavridou A. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi,



- and european origin populations: Cross sectional study. *BMJ (Clinical research ed.)*. 1999;319:215-220.
23. Bathula R, Hughes AD, Panerai RB, Potter JF, Mc GTSA, Tillin T, Shore AC, Hale R, Chambers J, Kooner J, Chaturvedi N. South asians have adverse cerebrovascular haemodynamics, despite equivalent blood pressure, compared with europeans. This is due to their greater hyperglycaemia. *International journal of epidemiology*. 2011;40:1490-1498.
  24. Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in england: Results from the health survey for england 2006. *Hypertension*. 2009;53:480-486.
  25. Millett C, Gray J, Saxena S, Netuveli G, Khunti K, Majeed A. Ethnic disparities in diabetes management and pay-for-performance in the uk: The wandsworth prospective diabetes study. *PLoS medicine*. 2007;4:e191.
  26. Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, Lip GY. Ischemic stroke in south asians: A review of the epidemiology, pathophysiology, and ethnicity-related clinical features. *Stroke; a journal of cerebral circulation*. 2009;40:e415-423.
  27. Acharya DU, Heber ME, Dore CJ, Raftery EB. Ambulatory intraarterial blood pressure in essential hypertension. Effects of age, sex, race, and body mass--the northwick park hospital database study. *American journal of hypertension*. 1996;9:943-952.
  28. Pires PW, Dams Ramos CM, Matin N, Dorrance AM. The effects of hypertension on the cerebral circulation. *American journal of physiology. Heart and circulatory physiology*. 2013;304:H1598-1614.

29. Park C, Bathula R, Shore AC, Tillin T, Strain WD, Chaturvedi N, Hughes AD. Impaired post-ischaemic microvascular hyperaemia in indian asians is unexplained by diabetes or other cardiovascular risk factors. *Atherosclerosis*. 2012;221:503-507.
30. Reinhard M, Wehrle-Wieland E, Grabiak D, Roth M, Guschlbauer B, Timmer J, Weiller C, Hetzel A. Oscillatory cerebral hemodynamics--the macro- vs. Microvascular level. *Journal of the neurological sciences*. 2006;250:103-109.
31. Wolfe CD, Rudd AG, Howard R, Coshall C, Stewart J, Lawrence E, Hajat C, Hillen T. Incidence and case fatality rates of stroke subtypes in a multiethnic population: The south london stroke register. *Journal of neurology, neurosurgery, and psychiatry*. 2002;72:211-216.

**Novelty and significance****What is new?**

- No studies compare associations between different blood pressure (BP) measures and stroke risk in South Asian and European groups.
- Mid-life systolic (SBP), diastolic (DBP) and mean arterial BP (MAP) were more strongly related to stroke risk in South Asian than European men. Associations between pulse pressure (PP) and stroke were similar.
- PP contributed most to stroke risk in Europeans, and MAP in South Asians.

**What is relevant?**

- Risk prediction scores are based on SBP, but DBP/ MAP may contribute more to stroke risk in South Asian groups.
- More aggressive BP treatment thresholds may be warranted to address the excess stroke risk experienced by South Asians.
- The different relative contributions of MAP and PP suggest ethnic differences in stroke pathogenesis.

**Summary**

Systolic, diastolic and mean arterial BP were more strongly associated with stroke risk in South Asian than European men.

**Figure legends**

**Figure 1. Follow-up of the SABRE cohort 1988-2011.**

**Figure 2. Proportions of incident stroke by blood pressure and HbA1c categories in European and South Asian men: for A) SBP in Europeans, B) SBP in South Asians, C) DBP in Europeans, and D) DBP in South Asians.** Excludes participants with baseline stroke or receipt of anti-hypertensive medication.

**Table 1. Baseline characteristics of European and South Asian men in the SABRE****study, by stroke status. Excludes participants with baseline stroke or receipt of anti-****hypertensive medication.** Data are n(%), median (IQR) or mean±SD. \*age-adjusted p for

difference in participants who experienced stroke vs. those who did not, †age-adjusted p for

ethnic difference, regardless of stroke status. HbA<sub>1c</sub> available for 1082 Europeans and 803

South Asians, eGFR available for 1015 Europeans and 959 South Asians.

Variable	Europeans				South Asians				
	All	No stroke	Stroke	p*	All	No stroke	Stroke	p*	p†
<b>n</b>	1375	1271 (92)	104(8)	-	1074	972 (90)	102 (10)	-	-
<b>Age, years</b>	52 (46-58)	52 (46-58)	51 (46-56)	<0.001	50 (45-55)	49 (44-55)	53 (48-59)	<0.001	<0.001
<b>Ever smoked</b>	1011 (74)	928 (73)	83 (80)	0.21	292 (27)	260 (27)	32(32)	0.27	<0.001
<b>Manual occupation</b>	852 (62)	778 (61)	74(71)	0.14	819 (77)	736 (76)	83(82)	0.17	<0.001
<b>Alcohol, units/ week</b>	12(3-26)	12(3-26)	13(1-31)	0.37	3 (0-15)	3(0-15)	4(0-20)	0.34	0.003
<b>Veg/ fruit daily/ most days</b>	931 (68)	862 (68)	69(66)	0.58	711 (67)	646 (67)	65(65)	0.36	0.99

<b>Physical activity, MJ/wk</b>	11(7-16)	12(7-16)	11(7-19)	0.06	10 (6-13)	10(6-13)	9(5-14)	0.08	<0.001
<b>Waist/hip ratio</b>	0.94±0.07	0.94±0.06	0.95±0.08	0.41	0.98±0.06	0.98±0.06	1.00±0.06	0.08	<0.001
<b>BMI, kg/m<sup>2</sup></b>	26.1±3.8	26.1±3.7	25.9±4.1	0.51	25.7±3.2	25.7±3.1	25.8±3.7	0.71	0.02
<b>HDL, mmol/l</b>	1.3 (1.1-1.5)	1.3 (1.1-1.5)	1.3 (1.1-1.5)	0.73	1.2 (1.0-1.4)	1.2 (1.0-1.4)	1.2 (1.0-1.4)	0.98	<0.001
<b>Triglycerides, mmol/l</b>	1.4 (1.0-2.1)	1.4 (1.0-2.1)	1.6 (1.1-2.2)	0.20	1.7 (1.2-2.5)	1.7 (1.2-2.5)	1.8 (1.1-2.6)	0.57	<0.001
<b>Total/ HDL cholesterol</b>	4.7 (3.8-5.9)	4.7 (3.8-5.9)	4.8 (3.9-5.6)	0.93	5.0 (4.2-6.1)	5.0 (4.2-6.1)	5.1 (4.4-6.1)	0.23	<0.001
<b>Diabetes</b>	84 (6)	76(6)	8(8)	0.92	212 (20)	168 (17)	44(43)	<0.001	<0.001
<b>Fasting glucose, mmol/l</b>	5.4 (5.1-5.9)	5.4 (5.1-5.9)	5.5 (5.1-5.9)	0.26	5.6 (5.2-6.2)	5.6 (5.1-6.1)	5.9 (5.3-7.7)	<0.001	<0.001
<b>Post-load glucose, mmol/l</b>	5.0 (4.1-5.9)	5.0 (4.1-5.9)	5.0 (3.9-5.8)	0.14	5.5 (4.6-6.6)	5.5 (4.6-6.5)	5.9 (4.8-8.3)	0.01	<0.001

	5.6	5.6	5.6		5.8	5.8	6.1		
<b>HbA1c, %</b>	(5.4-5.8)	(5.4-5.8)	(5.4-5.8)	0.24	(5.5-6.2)	(5.5-6.2)	(5.7-6.9)	0.02	<0.001
<b>HOMA2-IR</b>	0.8	0.8	0.7	0.69	1.2	1.2	1.4	0.04	<0.001
<b>eGFR, ml/min</b>	117±36	118±36	107±40	0.05	109±37	109±37	107±38	0.81	<0.001
<b>Median heart rate, bpm</b>	64 (57-72)	63 (57-72)	65 (56-71)	0.71	68 (61-75)	67 (61-75)	71 (63-77)	0.03	<0.001
<b>Systolic BP, mmHg</b>	122±16	122±16	127±22	0.05	124±17	123±17	134±17	<0.001	<0.001
<b>Diastolic BP, mmHg</b>	77±11	77±11	76±12	0.40	80±10	80±10	84±11	<0.001	<0.001
<b>Mean arterial BP, mmHg</b>	92±12	92±12	93±14	0.70	95±12	94±11	101±12	<0.001	<0.001
<b>Pulse pressure, mmHg</b>	45±12	45±12	50±17	0.001	44±13	43±12	50±13	0.003	0.90

**Table 2. Associations between baseline blood pressure measures and incident stroke, by ethnicity.** Excludes participants with baseline stroke or receipt of anti-hypertensive medication. Data are odds ratios (OR) for a 1SD increase in BP measure unless otherwise stated, \*p<0.05, †p<0.01, ‡p<0.001, §p for ethnicity x BP interaction. ||Cardiovascular disease (CVD) risk factors comprise: smoking, WHR, total/ HDL- cholesterol ratio, diabetes, fasting glucose, physical activity and heart rate. SBP=systolic blood pressure, DBP=diastolic blood pressure, MAP= mean arterial blood pressure, PP=pulse pressure.

BP measure	Model factors	Europeans		South Asians		p§
		OR	95% CI	OR	95% CI	
<b>SBP</b>	Age	1.21	1.00,1.47*	1.63	1.34,1.97‡	0.04
	Age + CVD risk factors	1.22	0.98,1.51	1.56	1.24,1.95‡	0.04
<b>DBP</b>	Age	0.91	0.74, 1.13	1.64	1.33,2.03‡	<0.001
	Age + CVD risk factors	0.90	0.71,1.13	1.68	1.32,2.15‡	<0.001
<b>MAP</b>	Age	1.04	0.85, 1.28	1.69	1.38,2.08‡	0.001
	Age + CVD risk factors	1.04	0.82,1.30	1.69	1.34,2.14‡	0.001
<b>PP</b>	Age	1.39	1.15, 1.68†	1.35	1.10, 1.64†	0.73
	Age + CVD risk factors	1.40	1.13,1.72†	1.24	0.99,1.55	0.80
<b>SBP</b>	Age	1.58	1.22,2.07†	1.38	1.04,1.82*	0.44
<b>DBP</b>	Age	0.66	0.50,0.87†	1.28	0.95,1.74	0.001



<b>SBP</b>	Age + CVD risk	1.59	1.20,2.13†	1.24	0.91,1.70	0.50
<b>DBP</b>	factors	0.66	0.49,0.89†	1.43	1.01,2.01†	0.001
<b>MAP</b>	Age	0.88	0.71,1.11	1.64	1.30,2.08‡	<0.001
<b>PP</b>	Age	1.46	1.18,1.81‡	1.06	0.84,1.34	0.04
<b>MAP</b>	Age + CVD risk	0.88	0.68,1.12	1.72	1.31,2.25‡	<0.001
<b>PP</b>	factors	1.47	1.17,1.85†	0.97	0.75,1.26	0.04

**Table 3. Associations between blood pressure measures and incident stroke in men, including participants in receipt of baseline anti-hypertensive medication.** A correction of +10/5 mmHg was added to the blood pressures of participants in receipt of anti-hypertensive medication. Data are odds ratios (OR) for a 1SD increase in BP measure unless otherwise stated, \*p<0.05, †p<0.01, ‡p<0.001, §p for ethnicity x BP interaction.

||Cardiovascular disease (CVD) risk factors comprise: smoking, WHR, total/ HDL-cholesterol ratio, diabetes, fasting glucose, physical activity and heart rate. SBP=systolic blood pressure, DBP=diastolic blood pressure, MAP= mean arterial blood pressure PP=pulse pressure.

BP meas ure	Model factors	Europeans		South Asians		p§
		OR	95% CI	OR	95% CI	
SBP	Age	1.32	1.11,1.57†	1.61	1.35,1.92‡	0.16
	Age + CVD risk factors	1.31	1.08,1.58†	1.52	1.25,1.86‡	0.16
DBP	Age	1.01	0.85,1.21	1.55	1.28,1.80‡	0.001
	Age + CVD risk factors	1.02	0.83,1.24	1.53	1.23,1.89‡	0.002
MAP	Age	1.15	0.97,1.38	1.64	1.36,1.97‡	0.009
	Age + CVD risk factors	1.16	0.95,1.41	1.58	1.29,1.95‡	0.01

	Age	1.44	1.21,1.70‡	1.39	1.17,1.66‡	0.61
<b>PP</b>	Age + CVD risk factors	1.40	1.16,1.67‡	1.29	1.06,1.57*	0.69

**Table 4. Associations between blood pressure and incident stroke, adjusting for presence of anti-thrombotic medication (anti-coagulant or anti-platelet agents) or atrial fibrillation at follow-up, by ethnicity.** Participants are men not in receipt of baseline anti-hypertensive medication with follow-up data for medication use and presence of atrial fibrillation; n=712 European and 584 South Asian men. Data are odds ratios (OR) for a 1SD increase in BP measure, \*p<0.05, †p<0.01, ‡p<0.001, §p for ethnicity x BP interaction. SBP=systolic blood pressure, DBP=diastolic blood pressure, MAP= mean arterial blood pressure PP=pulse pressure.

BP measur e	Model factors	Europeans		South Asians		p§
		OR	95% CI	OR	95% CI	
SBP	Age	1.02	0.76,1.36	1.68	1.28,2.20‡	0.02
	Age + anti-thrombotic medication at follow-up	0.90	0.66,1.22	1.57	1.18,2.08†	0.006
	Age + atrial fibrillation at follow-up	1.00	0.75,1.34	1.64	1.24,2.17	0.02
DBP	Age	0.82	0.62, 1.09	1.66	1.24,2.21†	0.001
	Age + anti-thrombotic medication at follow-up	0.78	0.58, 1.04	1.54	1.14,2.08†	0.001
	Age + atrial fibrillation at follow-up	0.83	0.63,1.10	1.58	1.18,2.13	0.002
MAP	Age	0.89	0.66, 1.19	1.70	1.29, 2.24‡	0.001

	Age + anti-thrombotic medication at follow-up	0.81	0.60,1.09	1.59	1.20,2.11†	0.001
	Age + atrial fibrillation at follow-up	0.88	0.66,1.19	1.64	1.24,2.18	0.002
	Age	1.20	0.92, 1.57	1.45	1.07, 1.95*	0.36
<b>PP</b>	Age + anti-thrombotic medication at follow-up	1.10	0.83,1.44	1.37	1.02,1.85*	0.21
	Age + atrial fibrillation at follow-up	1.17	0.90,1.54	1.45	1.08,1.97	0.27